---
figid: PMC7554788__ijms-21-06479-g001
figtitle: Action of CDK4/6 inhibitors
organisms:
- Homo sapiens
- Mus musculus
- Citrus macrophylla
- Subgroup A
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7554788
filename: ijms-21-06479-g001.jpg
figlink: pmc/articles/PMC7554788/figure/ijms-21-06479-f001/
number: F1
caption: Mechanism of action of CDK4/6 inhibitors. Activation of upstream signaling
  pathways, such as MAPK, PI3K, and ER, regulate the progression of cell cycle by
  promoting the formation of complex cyclin D-CDK4/6, which selectively phosphorylates
  and inactivates pRb protein. Rb proteins limit the expression of many E2F target
  genes which are involved in cell cycle progression, DNA replication, and mitotic
  progression. CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) selectively
  inhibit the downstream CDK4/6-mediated phosphorylation of Rb, leading to cell cycle
  arrest in G0/G1 phase. Combination strategies are focused on dual blockade of CDK4/6
  and upstream signaling, mainly mediated by ER, MAPK pathway and PI3K/AKT/mTOR pathway.
papertitle: 'Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.'
reftext: Michela Piezzo, et al. Int J Mol Sci. 2020 Sep;21(18):6479.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9003435
figid_alias: PMC7554788__F1
figtype: Figure
redirect_from: /figures/PMC7554788__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7554788__ijms-21-06479-g001.html
  '@type': Dataset
  description: Mechanism of action of CDK4/6 inhibitors. Activation of upstream signaling
    pathways, such as MAPK, PI3K, and ER, regulate the progression of cell cycle by
    promoting the formation of complex cyclin D-CDK4/6, which selectively phosphorylates
    and inactivates pRb protein. Rb proteins limit the expression of many E2F target
    genes which are involved in cell cycle progression, DNA replication, and mitotic
    progression. CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) selectively
    inhibit the downstream CDK4/6-mediated phosphorylation of Rb, leading to cell
    cycle arrest in G0/G1 phase. Combination strategies are focused on dual blockade
    of CDK4/6 and upstream signaling, mainly mediated by ER, MAPK pathway and PI3K/AKT/mTOR
    pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Zhx2
  - Akt1
  - Mtor
  - Ephb2
  - Mapk1
  - Cdk6
  - Cdk4
  - Igfals
  - Gabrg2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - CCND1
  - CCND2
  - CCND3
  - CDK6
  - CDK4
  - IGFALS
  - SOD1
  - AR
  - TP63
  - IS1
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - WARS1
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - Tor
  - Erk7
  - rl
  - CycD
  - rb
  - als
  - conv
  - nAChRalpha1
  - ais
  - ebi
  - E2f2
  - E2f1
  - LanB2
  - anon-70Db
  - CycE
  - cyc
  - anon-70Dc
  - TAMOXIFEN
---
